Hepatitis C Drug Market
Hepatitis C Drug Market - Global Industry Assessment & Forecast
#
Pages:
144
Base Year:
2022
Aug - 2023
Format:
Report Code:
VMR-2239
Segments Covered
By
Product Type NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Other Products
-
By
Disease Type Acute Hepatitis C, Chronic Hepatitis C
-
By
Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 21.9 Billion |
 Revenue 2030:
|
USD 56.5 Billion |
 Revenue CAGR
(2023 - 2030): |
14.5% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Hepatitis C Drug Market Segment Analysis
- Hepatitis C Drug Product Type Outlook (Revenue, USD Million, 2018 - 2030)
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Hepatitis C Drug Disease Type Outlook (Revenue, USD Million, 2018 - 2030)
- Acute Hepatitis C
- Chronic Hepatitis C
- Hepatitis C Drug Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
-
North America Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
-
North America Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- U.S.
- U.S. Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- U.S. Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- U.S. Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- U.S. Hepatitis C Drug Market, by Product Type
- Canada
- Canada Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Canada Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Canada Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Canada Hepatitis C Drug Market, by Product Type
-
Mexico
- Mexico Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Mexico Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Mexico Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Mexico Hepatitis C Drug Market, by Product Type
-
North America Hepatitis C Drug Market, by Product Type
- Europe
-
Europe Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
-
Europe Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
-
Europe Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- U. K.
- U.K. Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- U.K. Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- U.K. Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- U.K. Hepatitis C Drug Market, by Product Type
- France
- France Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- France Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- France Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- France Hepatitis C Drug Market, by Product Type
-
Germany
- Germany Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Germany Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Germany Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Germany Hepatitis C Drug Market, by Product Type
-
Italy
- Italy Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Italy Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Italy Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Italy Hepatitis C Drug Market, by Product Type
-
Spain
- Spain Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Spain Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Spain Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Spain Hepatitis C Drug Market, by Product Type
-
Rest of Europe
- Rest of Europe Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Rest of Europe Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Rest of Europe Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Rest of Europe Hepatitis C Drug Market, by Product Type
-
Europe Hepatitis C Drug Market, by Product Type
- Asia Pacific
-
Asia Pacific Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
-
Asia Pacific Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
-
Asia Pacific Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- China
- China Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- China Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- China Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- China Hepatitis C Drug Market, by Product Type
- Japan
- Japan Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Japan Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Japan Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Japan Hepatitis C Drug Market, by Product Type
-
Germany
- Germany Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Germany Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Germany Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Germany Hepatitis C Drug Market, by Product Type
-
India
- India Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- India Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- India Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- India Hepatitis C Drug Market, by Product Type
-
South Korea
- South Korea Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- South Korea Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- South Korea Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- South Korea Hepatitis C Drug Market, by Product Type
-
South East Asia
- South East Asia Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- South East Asia Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- South East Asia Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- South East Asia Hepatitis C Drug Market, by Product Type
-
Rest of Asia Pacific
- Rest of Asia Pacific Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Rest of Asia Pacific Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Rest of Asia Pacific Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Rest of Asia Pacific Hepatitis C Drug Market, by Product Type
-
Asia Pacific Hepatitis C Drug Market, by Product Type
- Latin America
-
Latin America Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
-
Latin America Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
-
Latin America Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Brazil
- Brazil Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Brazil Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Brazil Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Brazil Hepatitis C Drug Market, by Product Type
- Argentina
- Argentina Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Argentina Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Argentina Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Argentina Hepatitis C Drug Market, by Product Type
-
Rest of Latin America
- Rest of Latin America Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Rest of Latin America Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Rest of Latin America Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Rest of Latin America Hepatitis C Drug Market, by Product Type
-
Latin America Hepatitis C Drug Market, by Product Type
- Middle East & Africa
-
Middle East & Africa Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
-
Middle East & Africa Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
-
Middle East & Africa Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- GCC Countries
- GCC Countries Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- GCC Countries Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- GCC Countries Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- GCC Countries Hepatitis C Drug Market, by Product Type
- South Africa
- South Africa Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- South Africa Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- South Africa Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- South Africa Hepatitis C Drug Market, by Product Type
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Hepatitis C Drug Market, by Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
- Other Products
- Rest of Middle East & Africa Hepatitis C Drug Market, by Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
- Rest of Middle East & Africa Hepatitis C Drug Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels
- Rest of Middle East & Africa Hepatitis C Drug Market, by Product Type
-
Middle East & Africa Hepatitis C Drug Market, by Product Type
- North America
Vantage Market
Research | 11-Aug-2023
FAQ
Frequently Asked Question
What is the global demand for Hepatitis C Drug in terms of revenue?
-
The global Hepatitis C Drug valued at USD 21.9 Billion in 2022 and is expected to reach USD 56.5 Billion in 2030 growing at a CAGR of 14.5%.
Which are the prominent players in the market?
-
The prominent players in the market are AbbVie Inc. (U.S.), Gilead Sciences Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Janssen Pharmaceuticals Inc. (Belgium), Merck Sharp & Dohme Corp. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Vertex Pharmaceuticals Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Roche Holding AG (Switzerland), GlaxoSmithKline PLC (UK), Mylan N.V. (U.S.), Eli Lilly and Company (U.S.), Bayer AG (Germany), AstraZeneca PLC (UK), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd. (Israel).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 14.5% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Hepatitis C Drug include
- “Increased Awareness and Innovation of New Drugs is likely to direct the Hepatitis C Treatment Market.”
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Hepatitis C Drug in 2022.
